{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T21:56:28Z","timestamp":1775253388899,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T00:00:00Z","timestamp":1539475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,11,12]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Patients with common variable immunodeficiency (CVID) have increased fatigue compared with the general population. Fatigue is associated with lower quality of life (QoL), which is associated with higher mortality in CVID. This study aimed to determine the prevalence of self-reported fatigue for patients with CVID and to identify its possible drivers and burden on QoL. We analysed data from the 2013 Immune Deficiency Foundation (IDF) treatment survey. Answers were included from 873 CVID patients who responded (respondents). Of the 873 respondents included in the analysis, 671 (76\u00b79%) reported fatigue, of whom 400 (83\u00b77%) were receiving intravenous (i.v.) immunoglobulins (IVIG) and 271 (68\u00b76%) were receiving subcutaneous (s.c.) immunoglobulins. This difference in fatigue between patients receiving IVIG and SCIG was statistically significant (P\u00a0&amp;lt;\u00a00\u00b7001). Dose and frequency of immunoglobulin replacement therapy (IgGRT) did not affect fatigue prevalence. Fatigued patients on IVIG reported greater infection rates and required more anti-microbials during the wear-off period. Fatigued patients reported worse health status than non-fatigued patients, and had lower rates of employment, education, household income and school attendance than their non-fatigued counterparts. Fatigue is increased in CVID, especially among patients receiving IVIG, compared to SCIG. Fatigue has a significant impact on QoL and productivity in patients with CVID. Further studies to identify the mechanisms of fatigue are warranted to help advance therapeutic measures to treat this disease and improve patients\u2019 QoL and wellbeing.<\/jats:p>","DOI":"10.1111\/cei.13210","type":"journal-article","created":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T14:55:26Z","timestamp":1535727326000},"page":"327-338","source":"Crossref","is-referenced-by-count":19,"title":["Fatigue and the wear-off effect in adult patients with common variable immunodeficiency"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4633-1043","authenticated-orcid":false,"given":"J","family":"Hajjar","sequence":"first","affiliation":[{"name":"Baylor College of Medicine, Section of Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Kutac","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Section of Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N L","family":"Rider","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Section of Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F O","family":"Seeborg","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Section of Immunology, Allergy and Rheumatology, Texas Children's Hospital, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Scalchunes","sequence":"additional","affiliation":[{"name":"The Immune Deficiency Foundation, Towson, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Orange","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University, NYC, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,14]]},"reference":[{"key":"2021120808501277700_cei13210-bib-0001","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40629-014-0030-4","article-title":"Immunodeficiency in adults a practical guide for the allergist","volume":"23","author":"Hausmann","year":"2014","journal-title":"Allergo J Int"},{"key":"2021120808501277700_cei13210-bib-0002","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International Consensus Document (ICON): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2021120808501277700_cei13210-bib-0003","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2141.2009.07669.x","article-title":"Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions","volume":"145","author":"Chapel","year":"2009","journal-title":"Br J Haematol"},{"key":"2021120808501277700_cei13210-bib-0004","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood"},{"key":"2021120808501277700_cei13210-bib-0005","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaci.2016.08.030","article-title":"Noninfectious complications in patients with pediatric-onset common variable immunodeficiency correlated with defects in somatic hypermutation but not in class-switch recombination","volume":"139","author":"Almejun","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0006","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10875-016-0367-1","article-title":"Increased Incidence of fatigue in patients with primary immunodeficiency disorders: prevalence and associations within the US immunodeficiency network registry","volume":"37","author":"Hajjar","year":"2017","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0007","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s10875-017-0404-8","article-title":"Health-related quality of life in adult patients with common variable immunodeficiency disorders and impact of treatment","volume":"37","author":"Rider","year":"2017","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0008","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3389\/fimmu.2014.00605","article-title":"Longitudinal study on health-related quality of life in a cohort of 96 patients with common variable immune deficiencies","volume":"5","author":"Tabolli","year":"2014","journal-title":"Front Immunol"},{"key":"2021120808501277700_cei13210-bib-0009","first-page":"52","article-title":"Study of quality of life in adults with common variable immunodeficiency by using the Questionnaire SF-36","volume":"61","author":"Lopez-Perez","year":"2014","journal-title":"Rev Alerg Mex"},{"key":"2021120808501277700_cei13210-bib-0010","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/eurpub\/ckp113","article-title":"Fatigue and chronic fatigue syndrome-like complaints in the general population","volume":"20","author":"van't Leven","year":"2010","journal-title":"Eur J Public Health"},{"key":"2021120808501277700_cei13210-bib-0011","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1007\/s00520-016-3275-2","article-title":"Patient and health care provider perceptions of cancer-related fatigue and pain","volume":"24","author":"Williams","year":"2016","journal-title":"Support Care Cancer"},{"key":"2021120808501277700_cei13210-bib-0012","first-page":"4","article-title":"Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition","volume":"34","author":"Vogelzang","year":"1997","journal-title":"Semin Hematol"},{"key":"2021120808501277700_cei13210-bib-0013","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10875-014-0056-x","article-title":"Autoimmunity and inflammation in X-linked agammaglobulinemia","volume":"34","author":"Hernandez-Trujillo","year":"2014","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0014","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3324\/haematol.2013.093724","article-title":"Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia","volume":"99","author":"Efficace","year":"2014","journal-title":"Haematologica"},{"key":"2021120808501277700_cei13210-bib-0015","volume-title":"Unexplained fatigue in elderly","author":"National Institutes of Health (NIH)","year":"2007"},{"key":"2021120808501277700_cei13210-bib-0016","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3349\/ymj.2012.53.3.603","article-title":"Health related quality of life in common variable immunodeficiency","volume":"53","author":"Quinti","year":"2012","journal-title":"Yonsei Med J"},{"key":"2021120808501277700_cei13210-bib-0017","doi-asserted-by":"crossref","first-page":"c6149","DOI":"10.1136\/bmj.c6149","article-title":"Effect of retirement on major chronic conditions and fatigue: French GAZEL occupational cohort study","volume":"341","author":"Westerlund","year":"2010","journal-title":"BMJ"},{"key":"2021120808501277700_cei13210-bib-0018","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/ije\/dyp147","article-title":"A systematic review of chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping","volume":"38","author":"Dinos","year":"2009","journal-title":"Int J Epidemiol"},{"key":"2021120808501277700_cei13210-bib-0019","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/archinte.159.18.2129","article-title":"A community-based study of chronic fatigue syndrome","volume":"159","author":"Jason","year":"1999","journal-title":"Arch Intern Med"},{"key":"2021120808501277700_cei13210-bib-0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/A:1023263303987","article-title":"The relationship between ethnicity and fatigue in a community-based sample","volume":"4","author":"Sharon Song","year":"1999","journal-title":"J Gender Cult Health"},{"key":"2021120808501277700_cei13210-bib-0021","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0022","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/2047-783X-15-6-238","article-title":"Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency","volume":"15","author":"Hoffmann","year":"2010","journal-title":"Eur J Med Res"},{"key":"2021120808501277700_cei13210-bib-0023","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1007\/s10875-010-9400-y","article-title":"Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home","volume":"30","author":"Lucas","year":"2010","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0024","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1007\/s10875-012-9720-1","article-title":"Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis","volume":"32","author":"Abolhassani","year":"2012","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s10875-013-9876-3","article-title":"Bioavailability of IgG administered by the subcutaneous route","volume":"33","author":"Berger","year":"2013","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0026","doi-asserted-by":"crossref","first-page":"AB88","DOI":"10.1016\/j.jaci.2014.12.1219","article-title":"Evidence of wear-off effect from Ig infusion therapy in routine clinical practice","volume":"135","author":"Zbrozek","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0027","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s10875-016-0243-z","article-title":"Quantitative evidence of wear-off effect at the end of the intravenous IgG (IVIG) dosing cycle in primary immunodeficiency","volume":"36","author":"Rojavin","year":"2016","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0028","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2249.1993.tb03380.x","article-title":"The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions","volume":"92","author":"Gardulf","year":"1993","journal-title":"Clin Exp Immunol"},{"key":"2021120808501277700_cei13210-bib-0029","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaci.2004.06.053","article-title":"Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home","volume":"114","author":"Gardulf","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3389\/fimmu.2014.00629","article-title":"Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe","volume":"5","author":"Kerr","year":"2014","journal-title":"Front Immunol"},{"key":"2021120808501277700_cei13210-bib-0031","doi-asserted-by":"crossref","first-page":"S525","DOI":"10.1016\/j.jaci.2006.01.015","article-title":"Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology","volume":"117","author":"Orange","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0032","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2010-01-254417","article-title":"How I treat common variable immune deficiency","volume":"116","author":"Cunningham-Rundles","year":"2010","journal-title":"Blood"},{"key":"2021120808501277700_cei13210-bib-0033","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.iac.2008.06.006","article-title":"Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes","volume":"28","author":"Bonilla","year":"2008","journal-title":"Immunol Allergy Clin North Am"},{"key":"2021120808501277700_cei13210-bib-0034","first-page":"277","article-title":"Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases","volume":"6","author":"Kobrynski","year":"2012","journal-title":"Biologics"},{"key":"2021120808501277700_cei13210-bib-0035","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1524-4733.2007.00294.x","article-title":"The effect of perceived health status on patient satisfaction","volume":"11","author":"Xiao","year":"2008","journal-title":"Value Health"},{"key":"2021120808501277700_cei13210-bib-0036","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s10875-015-0196-7","article-title":"Perceived health in patients with primary immune deficiency","volume":"35","author":"Seeborg","year":"2015","journal-title":"J Clin Immunol"},{"key":"2021120808501277700_cei13210-bib-0037","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1037\/0278-6133.26.4.464","article-title":"Utility of a cognitive-behavioral model to predict fatigue following breast cancer treatment","volume":"26","author":"Donovan","year":"2007","journal-title":"Health Psychol"},{"key":"2021120808501277700_cei13210-bib-0038","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1200\/JCO.2000.18.4.743","article-title":"Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life","volume":"18","author":"Bower","year":"2000","journal-title":"J Clin Oncol"},{"key":"2021120808501277700_cei13210-bib-0039","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcei.13210","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/194\/3\/327\/41645841\/cei13210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/194\/3\/327\/41645841\/cei13210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:26:28Z","timestamp":1641054388000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/194\/3\/327\/6411856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,14]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,10,14]]},"published-print":{"date-parts":[[2018,11,12]]}},"URL":"https:\/\/doi.org\/10.1111\/cei.13210","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,12]]},"published":{"date-parts":[[2018,10,14]]}}}